|
Long-term utilization and benefit of luspatercept in patients (pts) with lower-risk myelodysplastic syndromes (LR-MDS) from the MEDALIST trial. |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Celgene/Bristol-Myers Squibb; Geron; Gilead Sciences; Menarini; Novartis |
|
|
Stock and Other Ownership Interests - Abbvie |
Consulting or Advisory Role - Abbvie; Acceleron Pharma; Bristol-Myers Squibb; Geron; Jazz Pharmaceuticals; Novartis |
Speakers' Bureau - Agios; Bristol-Myers Squibb; Jazz Pharmaceuticals |
Travel, Accommodations, Expenses - Agios; Bristol-Myers Squibb; Jazz Pharmaceuticals |
|
|
Honoraria - Abbvie; Acceleron Pharma; Agios; Astellas Pharma; BeyondSpring Pharmaceuticals; Boehringer Ingelheim; Bristol-Myers Squibb; Cardinal Health; Celgene; Daiichi Sankyo; Epizyme; Incyte; Ionis Pharmaceuticals; Jazz Pharmaceuticals; Novartis; Otsuka; Pfizer; Seagen; Taiho Pharmaceutical; Takeda; Trovagene |
Consulting or Advisory Role - Abbvie; Acceleron Pharma; Agios; Astellas Pharma; BeyondSpring Pharmaceuticals; Boehringer Ingelheim; Bristol-Myers Squibb; Cardinal Health; Celgene; Daiichi Sankyo; Epizyme; Incyte; Ionis Pharmaceuticals; Jazz Pharmaceuticals; Novartis; Otsuka; Pfizer; Seagen; Taiho Pharmaceutical; Takeda; Trovagene |
Research Funding - Abbvie (Inst); ADC Therapeutics (Inst); Aprea AB (Inst); Astex Pharmaceuticals (Inst); AstraZeneca/MedImmune (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Incyte (Inst); Novartis (Inst); Pfizer (Inst); Takeda (Inst); Trovagene (Inst) |
Travel, Accommodations, Expenses - Celgene; Novartis; Pfizer; Trovagene |
|
|
Honoraria - Abbvie; Acceleron Pharma; Astex Pharmaceuticals; Bristol-Myers Squibb/Celgene; Curis; Genentech; Gilead Sciences; Novartis |
Consulting or Advisory Role - Acceleron Pharma; Astex Pharmaceuticals; Bristol-Myers Squibb |
Research Funding - Abbvie; Aprea Therapeutics; Astex Pharmaceuticals; Bristol-Myers Squibb; Curis; Genentech; Gilead Sciences; Novartis |
|
|
Honoraria - Bristol-Myers Squibb; Taiho Pharmaceutical; Takeda |
Consulting or Advisory Role - Bristol-Myers Squibb; Taiho Pharmaceutical; Takeda |
Research Funding - Bristol-Myers Squibb; Takeda |
|
|
Employment - Bristol-Myers Squibb |
|
|
Employment - Bristol-Myers Squibb |
|
|
Employment - Bristol-Myers Squibb |
|
|
Employment - Bristol-Myers Squibb |
Stock and Other Ownership Interests - Bristol-Myers Squibb |
Patents, Royalties, Other Intellectual Property - Bristol-Myers Squibb |
|
|
Employment - Bristol-Myers Squibb |
|
|
Employment - Bristol-Myers Squibb |
|
|
Employment - Bristol-Myers Squibb |
Stock and Other Ownership Interests - Bristol-Myers Squibb |
|
|
|
Consulting or Advisory Role - Celgene/Jazz |
Research Funding - Amgen (Inst); BerGenBio (Inst); Celgene (Inst); Janssen (Inst); Novartis (Inst) |
Patents, Royalties, Other Intellectual Property - part of a patent for a TFR-2 antibody (Rauner et al. Nature Metabolics 2019) |
Travel, Accommodations, Expenses - Celgene |